Recent news coverage highlights Catalyst Pharmaceuticals' market momentum, strategic initiatives, and ongoing business developments in early 2026.

• Catalyst Pharmaceuticals is noted for positive market momentum and potential sustainability of its trend as of April 27, 2026 [N8].

Catalyst Pharmaceuticals has demonstrated strong financial performance with significant net income and robust liquidity, supporting ongoing operations and strategic initiatives. The company’s focus on orphan and rare diseases positions it in markets with high unmet medical needs and regulatory incentives. Its active share repurchase program indicates confidence in capital allocation. Experienced leadership and a well-established product portfolio provide a foundation for continued business development and potential expansion through acquisitions and clinical progress. Recent market commentary highlights positive momentum and investor interest in the company’s prospects [N8].

Catalyst faces risks from potential regulatory changes including tariffs on pharmaceutical imports and Most Favored Nation pricing policies, which could increase costs and affect international sales. The company’s reliance on third-party suppliers for active ingredients and finished products introduces supply chain risks. Market competition in orphan drug segments and challenges in clinical development could impact future product launches and revenue growth. Additionally, the company’s financial results and operational execution remain subject to uncertainties inherent in the pharmaceutical industry.

Catalyst Pharmaceuticals' moat is primarily based on its focus on orphan and rare disease markets, which typically have high barriers to entry due to regulatory exclusivities and specialized clinical development requirements. The company’s established products, such as FIRDAPSE® and AGAMREE®, benefit from niche market positioning and limited direct competition. Its experienced management team and strategic partnerships support product development and commercialization. Additionally, Catalyst’s strong liquidity and capital resources provide financial flexibility to pursue acquisitions and clinical programs, reinforcing its competitive position in the orphan drug sector.

• Tariffs and Import Costs: Potential tariffs on pharmaceutical imports could increase costs for active ingredients and finished products sourced internationally, impacting manufacturing and clinical trial timelines.
• Pricing Regulation Risks: Policies such as Most Favored Nation pricing could affect drug pricing structures in the U.S., potentially reducing revenues or margins.
• Supply Chain Dependence: Dependence on third-party suppliers, including Santhera and Eisai, for key products introduces risks related to supply disruptions or cost increases.
• Clinical and Regulatory Risks: Challenges in clinical development, regulatory approvals, and market acceptance could affect product launches and revenue streams.

• Catalyst Pharmaceuticals, Inc. is a Delaware corporation headquartered in Coral Gables, Florida.
• The company is publicly traded on NASDAQ under the ticker CPRX.
• As of April 27, 2026, there were 122,346,043 shares of common stock outstanding.
• The company focuses on pharmaceutical products, including orphan/rare disease treatments.
• Key products include FIRDAPSE® and AGAMREE®, with 2025 net revenues for FIRDAPSE® at least $362.9 million and AGAMREE® at least $122.1 million.
• Catalyst has a share repurchase program authorized for up to $200 million starting October 1, 2025, expiring December 31, 2026, with 405,092 shares repurchased as of November 3, 2025.
• The company reported cash and cash equivalents of $709.2 million as of December 31, 2025.
• Current assets were $894.0 million and current liabilities were $147.2 million as of December 31, 2025, resulting in a current ratio of 6.08 and a cash ratio of 4.82.
• Net income for the fiscal year ended December 31, 2025, was $214.3 million.
• Basic earnings per share for 2025 were $1.75 and diluted EPS was $1.68.
• The company’s board includes experienced pharmaceutical industry professionals, with Patrick J. McEnany as Non-Executive Chairman and co-founder, and Richard J. Daly as President and CEO since January 1, 2024.
• Catalyst sources active pharmaceutical ingredients and finished products from both U.S. and foreign suppliers, including Santhera for AGAMREE® and Eisai for FYCOMPA® through at least 2029.
• The company faces risks related to potential tariffs on pharmaceutical imports and Most Favored Nation pricing policies that could affect costs and sales.
• Catalyst has a focus on orphan drug development and commercialization, with ongoing clinical trials and strategic acquisition targets.
• The company has established corporate goals including revenue targets and clinical study enrollment milestones for 2025.
• Recent news coverage highlights Catalyst’s market momentum and business developments as of early 2026.
• The company’s executive compensation program is aligned with market practices and includes base salary, short-term incentives, and long-term equity awards.
• Catalyst’s liquidity position as of December 31, 2025, is strong, with substantial cash reserves relative to liabilities.